About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
Submit
November 7, 2022
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
August 31, 2022
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
August 11, 2022
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 1, 2022
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
June 29, 2022
Verrica Announces Pricing of Public Offering of Common Stock
1
2
3
next >
